Acadia Faces EU Setback On Trofinetide As Valuation Signals Diverge [Yahoo! Finance]
ACADIA Pharmaceuticals Inc. (ACAD)
Last acadia pharmaceuticals inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-irhome
Company Research
Source: Yahoo! Finance
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. The European Medicines Agency's CHMP issued a negative opinion on ACADIA Pharmaceuticals' trofinetide for Rett syndrome in Europe. The committee cited concerns around trial design and limited efficacy data in its assessment. ACADIA plans to request a re examination, which could extend timelines for potential European approval and commercialization. ACADIA Pharmaceuticals, listed as NasdaqGS:ACAD, now faces a meaningful regulatory setback in Europe after CHMP's negative view of trofinetide for Rett syndrome. The stock last closed at $23.39, with a 7 day return of a 6.3% decline and a 30 day return of a 10.5% decline, while the 1 year return stands at 29.4%. This mix of shorter term pressure and stronger 1 year performance frames how investors may reassess risk around the Rett opportunity outside the U.S. The planned re examination introduces extra timing an
Show less
Read more
Impact Snapshot
Event Time:
ACAD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACAD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACAD alerts
High impacting ACADIA Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
ACAD
News
- Is It Time To Revisit ACADIA Pharmaceuticals (ACAD) After Recent Share Price Weakness? [Yahoo! Finance]Yahoo! Finance
- ACADIA Pharmaceuticals (ACAD) had its price target raised by JPMorgan Chase & Co. from $31.00 to $34.00. They now have an "overweight" rating on the stock.MarketBeat
- Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of DirectorsBusiness Wire
- ACADIA Pharmaceuticals (ACAD) had its "neutral" rating reaffirmed by Bank of America Corporation.MarketBeat
ACAD
Earnings
- 2/25/26 - Beat
ACAD
Sec Filings
- 3/5/26 - Form 8-K
- 2/26/26 - Form SCHEDULE
- 2/26/26 - Form 10-K
- ACAD's page on the SEC website